LXRX

Lexicon Pharmaceuticals (LXRX)

About Lexicon Pharmaceuticals (LXRX)

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Details

Daily high

Daily low

Price at open

52 Week High

$2.68

52 Week Low

$1.02

Market cap

1.0B

Dividend yield

0.00%

Volume

26,063

Avg. volume

2.8M

P/E ratio

-33.01

Lexicon Pharmaceuticals News